The mushrooms that make you trip belong primarily to the genus Psilocybe, which contains the psychoactive compounds psilocybin and psilocin. Over 200 species of fungi produce these compounds, but Psilocybe cubensis is by far the most widely known and commonly encountered. A second, very different mushroom, Amanita muscaria (the red-capped “fly agaric” from fairy tales), also produces psychoactive effects, but through an entirely separate chemical mechanism.
Psilocybin Mushrooms: The Main Species
Psilocybe cubensis is the species most people mean when they say “magic mushrooms.” It grows naturally in tropical and subtropical climates, thrives on cattle dung, and is the most widely cultivated species worldwide. Its total psilocybin and psilocin content ranges from about 0.85% to 1.45% of dry weight, depending on the strain. Among commonly cultivated strains, Creeper tends to be the most potent (averaging 1.36%), while Thai Cubensis sits at the lower end (around 0.88%).
Psilocybe azurescens, found along the Pacific coast of the United States, is considered one of the most potent psilocybin mushrooms in the wild. Psilocybe cyanescens, sometimes called “wavy caps,” grows on wood chips in temperate regions of North America and Europe and is also significantly stronger than cubensis. Psilocybe semilanceata, or the liberty cap, is the most common wild psilocybin species in Europe and parts of North America, recognized by its small, pointed, conical cap.
Beyond Psilocybe, the genus Panaeolus also includes hallucinogenic species. Of 77 known Panaeolus species, about 20 have reported psychoactive properties. Panaeolus cyanescens (not to be confused with Psilocybe cyanescens) is the most notable, found across tropical regions from Brazil and India to Australia, Thailand, and parts of the United States. Panaeolus cinctulus, sometimes called the banded mottlegill, grows in lawns and grassy areas in temperate climates.
Amanita Muscaria: A Different Kind of Trip
Amanita muscaria, the iconic red mushroom with white spots, is psychoactive but works nothing like psilocybin mushrooms. Its active compound, muscimol, targets the brain’s GABA system, the same inhibitory network that alcohol and sedatives act on. This produces a sedating, dreamlike state with euphoria, dizziness, impaired coordination, and visual distortions. Its precursor compound, ibotenic acid, converts to muscimol when the mushroom is dried or heated.
Because muscimol does not interact with serotonin receptors at all, the Amanita experience is fundamentally different from a psilocybin trip. People often describe it as more delirious and sedating than the emotionally vivid, perception-shifting experience of psilocybin. The line between a psychoactive dose and a toxic dose is also narrower, making it considerably riskier.
How Psilocybin Works in the Brain
When you eat a psilocybin mushroom, your body quickly strips a phosphate group off the psilocybin molecule, converting it into psilocin. Psilocin is the compound that actually crosses into the brain and produces the trip. It does this by binding to serotonin receptors, specifically the 5-HT2A receptor, and activating them in a pattern that ordinary serotonin does not. This activation triggers unique signaling pathways inside neurons that other compounds targeting the same receptor fail to produce, which is why psilocin causes hallucinations while some closely related molecules used in migraine or Parkinson’s treatment do not.
One of the most well-documented brain effects is disruption of the default mode network, the set of brain regions active when you’re daydreaming, reflecting on yourself, or thinking about the past and future. Psilocybin consistently reduces the internal connectivity of this network while increasing communication between brain regions that don’t normally talk to each other. This is thought to explain the dissolution of the sense of self, the feeling of ego loss, and the unusual connections between thoughts, emotions, and senses that characterize a trip. In studies of people with depression, this loosening of default mode network activity has been observed lasting up to three weeks after a single dose.
What the Experience Feels Like and How Long It Lasts
Effects begin 20 to 50 minutes after eating dried mushrooms, though the range can stretch from as little as 5 minutes to as long as 90 minutes depending on stomach contents and individual metabolism. Peak intensity typically hits between 60 and 130 minutes in. The full experience lasts 4 to 6 hours, with some people reporting residual effects for up to 12 hours.
Physically, psilocybin raises heart rate and blood pressure. Nausea is common, especially in the first hour. Some people vomit. Psychologically, the range is enormous. Many people experience vivid visual distortions, a sense of deep emotional connection, synesthesia (where senses blur together), and profound shifts in how they perceive time. Emotions tend to be amplified in every direction. The same compound that can produce a feeling of transcendent bliss can also trigger intense fear, anxiety, or paranoia, what’s commonly called a “bad trip.” The risk of poor mental health outcomes is higher outside supervised settings.
Dose Ranges for Dried Psilocybe Cubensis
Dosing varies significantly by species and individual sensitivity, but for dried Psilocybe cubensis, the most commonly referenced benchmarks come from clinical research. A standard dose is around 2.5 grams of dried mushroom, which corresponds to roughly 25 mg of pure psilocybin. A high dose is about 3.5 grams, and a supratherapeutic dose (used in some research settings) is 5 to 6 grams. These conversions assume approximately 1% psilocybin content per gram of dried mushroom.
If you were using a more potent species like Psilocybe azurescens or cyanescens, these gram amounts would need to be substantially lower to reach the same effect. Potency varies not only between species but between individual flushes of the same species, so there’s inherent unpredictability in dosing with whole mushrooms.
Dangerous Lookalikes
One of the most serious risks with wild mushrooms is misidentification. Galerina marginata, the “deadly galerina,” contains the same toxins as death cap mushrooms and can destroy the liver. It grows on rotting wood, has a brownish cap 1.5 to 5 cm across, and can look similar to small Psilocybe species growing in the same environments.
Spore color is one of the most reliable ways to tell them apart. Psilocybe species produce dark brownish-purple spores, while Galerina produces rusty, reddish-brown spores. Galerina also tends to have narrower stems, typically under 0.6 cm wide. In older specimens, the ring on the Galerina stem may be nearly invisible, removing one of the more obvious distinguishing features. Misidentifying a deadly galerina as a psilocybin mushroom is a well-documented cause of poisoning.
Legal Status
Psilocybin remains a controlled substance in most countries and in most U.S. states. Oregon was the first state to create a regulated framework for supervised psilocybin use. Colorado followed in 2022, decriminalizing personal cultivation, possession, and consumption of psychedelic mushrooms for adults 21 and older, and it granted its first license for a psilocybin healing center in April 2025. Utah created a pilot program in 2024 allowing two health care systems to offer psilocybin treatments. Several other states have pending legislation as of 2025, but Oregon and Colorado remain the only two with any form of legal access currently in place.